Collplant Biotechnologies LTD Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
The Loewenbaum Group has disclosed an increased beneficial ownership in CollPlant Biotechnologies, acquiring significant shares and warrants through a securities purchase agreement.
NASDAQ
The Loewenbaum Group has amended its Schedule 13D filing, disclosing a significant investment in CollPlant Biotechnologies Ltd. through a recent securities purchase agreement.
NASDAQ
SCHEDULE 13D/A: Insider Sells Collplant Shares, Ownership Drops to 12.9%
Ami Sagy, a significant beneficial owner, has reduced his stake in Collplant Biotechnologies Ltd. by selling 140,000 ordinary shares, bringing his total ownership to 12.9%.
NASDAQ
A group of significant shareholders, including George Walter Loewenbaum, has withdrawn its request to nominate Nachum Homi Shamir to CollPlant Biotechnologies' Board of Directors.
NASDAQ
A group of investors, holding 15.8% of CollPlant Biotechnologies, is advocating for immediate changes to the company's Board of Directors, including a new Chairman.
NASDAQ
The Loewenbaum family and associated entities have disclosed a collective beneficial ownership of 13.4% in CollPlant Biotechnologies Ltd for investment purposes.